Literature DB >> 5310143

International reference preparation of rheumatoid arthritis serum.

S G Anderson, M W Bentzon, V Houba, P Krag.   

Abstract

The National Institute for Medical Research, London, England, was requested by the WHO Expert Committee on Biological Standardization to arrange a collaborative study of the serum pool they had obtained, to determine its suitability to serve as an international reference preparation of rheumatoid arthritis serum. A batch of this serum was assayed by 11 laboratories in 7 countries against 30 test preparations. On the basis of the results obtained, the serum has been established as the International Reference Preparation of Rheumatoid Arthritis Serum and the International Unit of Rheumatoid Arthritis Serum has been defined as the activity contained in 0.171 mg of the international reference preparation.A description is also given of the British reference preparation of rabbit antibody to sheep red blood cells (amboceptor) and this material was also tested in the collaborative study.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5310143      PMCID: PMC2427447     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  3 in total

1.  THE PROBLEM OF STANDARDIZATION IN RHEUMATOID ARTHRITIS SEROLOGY.

Authors:  S BOZSOKY
Journal:  Arthritis Rheum       Date:  1963-10

2.  The F-II-bentonite flocculation test (F-II-BFT) for rheumatoid arthritis. A comparison of results from six laboratories.

Authors:  J P NASOU; D E KAYHOE; J BOZICEVICH
Journal:  Tech Bull Regist Med Technol       Date:  1963-06

3.  The stability of biological standards.

Authors:  N K JERNE; W L PERRY
Journal:  Bull World Health Organ       Date:  1956       Impact factor: 9.408

  3 in total
  35 in total

1.  Progress in standardization: 4 immunological reagents.

Authors:  I Batty
Journal:  Bull World Health Organ       Date:  1976       Impact factor: 9.408

2.  Significance of rheumatoid factors in an eight-year longitudinal study on arthritis.

Authors:  T Tuomi; K Aho; T Palosuo; K Kaarela; R von Essen; H Isomäki; M Leirisalo-Repo; S Sarna
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

3.  Center for disease control diagnostic immunology proficiency testing program results for 1976.

Authors:  R N Taylor; K M Fulford; A Przybyszewski; V Pope
Journal:  J Clin Microbiol       Date:  1977-09       Impact factor: 5.948

4.  A human monoclonal IgA rheumatoid factor using the VkIV light chain gene.

Authors:  R Mierau; A Gause; R Küppers; M Michels; R A Mageed; R Jefferis; E Genth
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

5.  Standardisation of the quantitative determination of antinuclear antibodies (ANAs) with a homogeneous pattern.

Authors:  T E Feltkamp; F Klein; M B Janssens
Journal:  Ann Rheum Dis       Date:  1988-11       Impact factor: 19.103

6.  Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis.

Authors:  L Vasiliauskiene; A Wiik; M Høier-Madsen
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

7.  Reduction of variation in results of rheumatoid factor tests by use of a serum reference preparation.

Authors:  R N Taylor; K M Fulford; W L Jones
Journal:  J Clin Microbiol       Date:  1977-01       Impact factor: 5.948

8.  Reference preparation to standardize results of serological tests for rheumatoid factor.

Authors:  K M Fulford; R N Taylor; V A Przybyszewski
Journal:  J Clin Microbiol       Date:  1978-05       Impact factor: 5.948

9.  Clinical and serological features of severe vasculitis in rheumatoid arthritis: prognostic implications.

Authors:  A J Geirsson; G Sturfelt; L Truedsson
Journal:  Ann Rheum Dis       Date:  1987-10       Impact factor: 19.103

10.  Enhancement of human lymphocyte transformation by aggregated human gamma globulin.

Authors:  T D Kinsella
Journal:  J Clin Invest       Date:  1974-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.